Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback